Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.

Clinical pharmacokinetics - 1 Jan 2009

Ververs F F Tessa, Voorbij Heronimus A M, Zwarts Petra, Belitser Svetlana V, Egberts Toine C G, Visser Gerard H A, Schobben Alfred F A M

Abstract excerpt

BACKGROUND AND OBJECTIVE: Increasing numbers of women in childbearing years are treated with antidepressants. Concerns regarding fetal exposure to medication has led to large studies on drug effects on birth outcome and on the risk of congenital anomalies. The risk of adverse effects due to paroxetine use during pregnancy has been associated with the extent of exposure. Nevertheless, few studies have covered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Depression

Share to Drug Monitoring

Share to Paroxetine

Share to Pharmacogenetics

Share to Pregnancy

Share to Surveys and Questionnaires

Source

Identifiers

PMID: 19743889
DOI: 10.2165/11318050-000000000-00000

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.PMID 19743889Read ↗

Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.Semantic proximity Read ↗

Impact of CYP2D6 Genotype on Paroxetine Serum Concentration.Semantic proximity Read ↗

Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy.Semantic proximity Read ↗

CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.Semantic proximity Read ↗

CYP2D6 genotypes and depressive symptoms during late pregnancy and postpartum.Semantic proximity Read ↗

Clinical implications of selective serotonin reuptake inhibitors-selective serotonin norepinephrine reuptake inhibitors pharmacogenetics during pregnancy and lactation.Semantic proximity Read ↗

Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes.Semantic proximity Read ↗

Pharmacogenomic Characterization of Childbearing-Aged Individuals With Mood Disorders in a Tertiary Care Perinatal Mental Health Clinic.Semantic proximity Read ↗

Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study.Semantic proximity Read ↗

Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug dispositionSemantic proximity Read ↗

Impact of Pregnancy and Vitamin A Supplementation on CYP2D6 Activity.Semantic proximity Read ↗

Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.